Literature DB >> 22507533

Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer.

Edward J Tanner1, Kara C Long, Qin Zhou, Rachel M Brightwell, Ginger J Gardner, Nadeem R Abu-Rustum, Mario M Leitao, Yukio Sonoda, Richard R Barakat, Alexia Iasonos, Dennis S Chi.   

Abstract

OBJECTIVES: To evaluate the impact of operative start time (OST) on surgical outcomes in patients with advanced ovarian cancer.
METHODS: All stage IIIB-IV serous ovarian cancer patients who underwent primary surgery at our institution from 1/01 to 1/10 were identified. Fourteen factors were evaluated for an association with surgical outcomes including OST and OR tumor index (1 point each for carcinomatosis and/or bulky [≥ 1 cm] upper abdominal disease). Univariate logistic regression considering within-surgeon clustering was performed for cytoreduction to ≤ 1 cm versus >1cm residual disease. In patients with ≤ 1 cm residual disease, univariate logistic regression considering within-surgeon clustering was performed for 1-10mm residual disease versus complete gross resection (CGR, 0mm residual). A multivariate logistic model was developed based on univariate analysis results in the ≤ 1 cm residual disease cohort.
RESULTS: Of 422 patients, residual disease was: 0mm, 144 (34.1%); 1-10mm, 175 (41.5%); >10mm, 103 (23.3%). OST was not associated with cytoreduction to ≤ 1 cm residual disease on univariate analysis. In the ≤ 1 cm residual disease cohort, albumin, CA-125, ascites, ASA score, stage, OR tumor index, and OST were associated with CGR on univariate analysis. Earlier OSTs were associated with increased rates of CGR. On multivariate analysis, CA-125 was independently associated with CGR. OST was associated with CGR in patients with an OR tumor index of 2 but not an OR tumor index<2.
CONCLUSIONS: OST was not associated with cytoreduction to ≤ 1 cm residual disease in patients with advanced serous ovarian cancer. In the cohort of patients with ≤ 1 cm residual disease, later OSTs were associated with reduced rates of CGR in patients with greater tumor burden.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22507533      PMCID: PMC4831057          DOI: 10.1016/j.ygyno.2012.04.014

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  27 in total

Review 1.  Optimal primary surgical treatment for advanced epithelial ovarian cancer.

Authors:  Ahmed Elattar; Andrew Bryant; Brett A Winter-Roach; Mohamed Hatem; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2011-08-10

2.  Effect of sleep deprivation on surgeons' dexterity on laparoscopy simulator.

Authors:  N J Taffinder; I C McManus; Y Gul; R C Russell; A Darzi
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321

3.  Cognitive performance and mood after a weekend on call in a surgical unit.

Authors:  K A Wesnes; M B Walker; L G Walker; S D Heys; L White; R Warren; O Eremin
Journal:  Br J Surg       Date:  1997-04       Impact factor: 6.939

4.  Time of day effects on the incidence of anesthetic adverse events.

Authors:  M C Wright; B Phillips-Bute; J B Mark; M Stafford-Smith; K P Grichnik; B C Andregg; J M Taekman
Journal:  Qual Saf Health Care       Date:  2006-08

5.  Operation timing does not affect outcome after coronary artery bypass graft surgery.

Authors:  Paul J Tan; Meng Xu; Daniel I Sessler; C Allen Bashour
Journal:  Anesthesiology       Date:  2009-10       Impact factor: 7.892

6.  Does late night hip surgery affect outcome?

Authors:  Aron T Chacko; Miguel A Ramirez; Arun J Ramappa; Lars C Richardson; Paul T Appleton; Edward K Rodriguez
Journal:  J Trauma       Date:  2011-08

7.  Do house officers learn from their mistakes?

Authors:  A W Wu; S Folkman; S J McPhee; B Lo
Journal:  JAMA       Date:  1991-04-24       Impact factor: 56.272

8.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors:  Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

9.  Impact of the 80-hour work week on mortality and morbidity in trauma patients: an analysis of the National Trauma Data Bank.

Authors:  C Anne Morrison; Matthew M Wyatt; Matthew M Carrick
Journal:  J Surg Res       Date:  2008-07-09       Impact factor: 2.192

10.  Time-of-day effects on surgical outcomes in the private sector: a retrospective cohort study.

Authors:  Rachel R Kelz; Timothy T Tran; Patrick Hosokawa; William Henderson; E Carter Paulson; Francis Spitz; Barton H Hamilton; Bruce L Hall
Journal:  J Am Coll Surg       Date:  2009-07-24       Impact factor: 6.113

View more
  6 in total

1.  Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?

Authors:  Jill H Tseng; Renee A Cowan; Qin Zhou; Alexia Iasonos; Maureen Byrne; Tracy Polcino; Clarissa Polen-De; Ginger J Gardner; Yukio Sonoda; Oliver Zivanovic; Nadeem R Abu-Rustum; Kara Long Roche; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2018-08-17       Impact factor: 5.482

2.  Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?

Authors:  Vasileios D Sioulas; Maria B Schiavone; David Kadouri; Oliver Zivanovic; Kara Long Roche; Roisin O'Cearbhaill; Nadeem R Abu-Rustum; Douglas A Levine; Yukio Sonoda; Ginger J Gardner; Mario M Leitao; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2017-02-21       Impact factor: 5.482

3.  Intraoperative Handoffs and Postoperative Complications Among Patients Undergoing Gynecologic Oncology Operations.

Authors:  Kemi M Doll; Jessica A Lavery; Anna C Snavely; Paola A Gehrig
Journal:  J Healthc Qual       Date:  2017 Jul/Aug       Impact factor: 1.095

4.  Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.

Authors:  Alli M Straubhar; Jennifer L Wolf; Ms Qin C Zhou; Alexia Iasonos; Stephanie Cham; Jason D Wright; Kara Long Roche; Dennis S Chi; Oliver Zivanovic
Journal:  Gynecol Oncol       Date:  2020-12-04       Impact factor: 5.482

5.  Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites.

Authors:  Tomer Feigenberg; Blaise Clarke; Carl Virtanen; Anna Plotkin; Michelle Letarte; Barry Rosen; Marcus Q Bernardini; Alexandra Kollara; Theodore J Brown; K Joan Murphy
Journal:  Biomed Res Int       Date:  2014-05-25       Impact factor: 3.411

6.  Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study.

Authors:  Thomas Boerner; Henry S Walch; Bastien Nguyen; Alexia Iasonos; Qin C Zhou; Nikolaus Schultz; M Herman Chui; Rachel N Grisham; William P Tew; Roisin E O'Cearbhaill; Carol Aghajanian; Oliver Zivanovic; Nadeem R Abu-Rustum; Ginger J Gardner; Yukio Sonoda; Dennis S Chi; Kara Long Roche
Journal:  Gynecol Oncol       Date:  2020-12-30       Impact factor: 5.482

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.